PY NETS IN 2024
e possible through investment to Dr. Xianxin Hua at the
s a cutting-edge approach to treating NETS. This innovative therapy involves modifying a patient's bringing this technology to human trial is a testament to the impact of patient support in pushing
nnouncement: ilestone in cancer therapy: a first-in-human CAR T cell therapy clinical trial for neuroendocrine cal research that led to the development of this therapy. eclinical developments from Dr. Hua’s lab and developed the CDH17 CAR T cell therapy, CHM r a clinical trial, which will begin patient enrollment in 2024. This first clinical trial will investigate H17 CAR T cell therapy in clinical trials, potentially revolutionizing the treatment for NETs. s important clinical trial,” said Elyse Gellerman, CEO of NETRF. “This milestone demonstrates sk, high-reward science to develop new treatments.” NETRF’s investment in this laboratory T cell technology to neuroendocrine cancer, an uncommon cancer that could as easily been NETRF Director of Research, initiated the collaboration by contacting Carl June, MD, Xianxin ge them to investigate the use of CAR T for NETs. A 2014 NETRF grant funded the initial work, to everyone involved in developing this potential therapy from an exciting possibility into a phase patient care. Years ago NETRF had a desire to accelerate the development of this therapy for
py, which includes treatments that empower a patient’s own immune system to fight cancer. One ls engineered to target and kill cancer cells. While CAR T cells have shown success in blood cluding difficulty identifying suitable targets on cancer cells that can be recognized by the therapy
Made with FlippingBook flipbook maker